Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| HROW - Harrow Health | 10.94% | Add +1.3% | 3,332,732 | $7.28 | $24M | +41,389 | +$2M |
| OCUL - Ocular Therapeutix | 10.83% | Hold | 5,974,800 | $4.02 | $24M | — | — |
| CDXS - Codexis | 6.07% | Reduce −4.2% | 1,288,450 | $10.46 | $13M | −56,550 | −$14M |
| CRNX - Crinetics Pharmaceuticals | 5.64% | Reduce −3.1% | 671,300 | $18.65 | $13M | −21,700 | −$3M |
| CYTK - Cytokinetics | 5.36% | Reduce −25.6% | 302,500 | $39.29 | $12M | −104,000 | −$3M |
| TELA - Tela Bio | 5.19% | Add +244.5% | 1,643,367 | $7.01 | $12M | +1,166,367 | +$6M |
| Protara Therapeutics | 4.00% | Add +0.4% | 2,684,167 | $3.31 | $9M | +10,136 | −$5M |
| Tracon Pharmaceuticals | 3.72% | Add +30.8% | 4,125,322 | $2.00 | $8M | +970,224 | −$47K |
| Kiniksa Pharmaceuticals · CL A | 3.56% | Reduce −26.8% | 814,250 | $9.69 | $8M | −298,250 | −$3M |
| Merus | 3.45% | Hold | 338,000 | $22.64 | $8M | — | — |
| Keros Therapeutics | 3.44% | Add +3.9% | 276,000 | $27.63 | $8M | +10,250 | −$7M |
| Inhibrx | 3.02% | New | 590,000 | $11.35 | $7M | +590,000 | +$7M |
| ETON - Eton Pharmaceuticals | 2.91% | Add +3.5% | 2,462,500 | $2.62 | $6M | +83,225 | −$4M |
| XOMA - XOMA Del | 2.64% | Reduce −2.9% | 263,050 | $22.28 | $6M | −7,950 | −$2M |
| Reata Pharmaceuticals · CLASS A | 2.52% | Reduce −54.9% | 183,750 | $30.39 | $6M | −223,252 | −$8M |
| Cutera | 2.50% | New | 147,700 | $37.50 | $6M | +147,700 | +$6M |
| Mersana Therapeutics | 2.18% | Add +47.5% | 1,047,000 | $4.62 | $5M | +337,000 | +$2M |
| PCVX - Vaxcyte | 1.86% | Reduce −10.0% | 190,000 | $21.76 | $4M | −21,000 | −$962K |
| STXS - Stereotaxis | 1.74% | Reduce −12.3% | 2,099,971 | $1.84 | $4M | −295,629 | −$5M |
| EWTX - Edgewise Therapeutics | 1.62% | Add +49.0% | 451,400 | $7.96 | $4M | +148,400 | +$654K |
| MASS - 908 Devices | 1.54% | Hold | 166,406 | $20.59 | $3M | — | — |
| Chimerix | 1.34% | Reduce −75.8% | 1,430,000 | $2.08 | $3M | −4,473,450 | −$24M |
| Fortress Biotech | 1.23% | Reduce −13.4% | 3,247,180 | $0.8398 | $3M | −502,820 | −$2M |
| CLDX — | 1.09% | Reduce −54.0% | 90,000 | $26.96 | $2M | −105,500 | −$4M |
| LQDA - Liquidia | 1.02% | Add +191.7% | 521,500 | $4.36 | $2M | +342,700 | +$990K |
| FDMT - 4D Molecular Therapeutics | 1.02% | Hold | 325,000 | $6.98 | $2M | — | — |
| PRQR - Proqr Therapeutics | 0.96% | Add +13.0% | 2,740,000 | $0.7777 | $2M | +315,000 | −$64K |
| URGN - Urogen Pharma | 0.88% | New | 238,670 | $8.19 | $2M | +238,670 | +$2M |
| Ginkgo Bioworks · CLASS A | 0.87% | Reduce −12.3% | 815,000 | $2.38 | $2M | −114,780 | −$2M |
| Verastem | 0.83% | Reduce −31.6% | 1,590,000 | $1.16 | $2M | −735,000 | −$1M |
| LRMR - Larimar Therapeutics | 0.82% | Reduce −1.2% | 932,814 | $1.96 | $2M | −10,888 | −$2M |
| Hyperfine · CL A | 0.77% | Hold | 763,075 | $2.23 | $2M | — | — |
| RYTM - Rhythm Pharmaceuticals | 0.68% | New | 362,000 | $4.15 | $2M | +362,000 | +$2M |
| Modular Medical | 0.64% | Add +3.5% | 275,422 | $5.18 | $1M | +9,322 | +$256K |
| Impel Pharmaceuticals | 0.61% | New | 144,642 | $9.32 | $1M | +144,642 | +$1M |
| Graphite Bio | 0.57% | Add +80.0% | 460,000 | $2.75 | $1M | +204,500 | −$38K |
| DERM - Journey Medicine | 0.41% | Add +266.8% | 245,733 | $3.74 | $919K | +178,733 | +$595K |
| Neoleukin Therapeutics | 0.28% | Reduce −22.8% | 610,000 | $1.03 | $628K | −180,000 | −$857K |
| Macrogenics | 0.28% | Reduce −44.7% | 208,300 | $2.95 | $614K | −168,100 | −$3M |
| Neuropace | 0.20% | New | 90,100 | $4.95 | $446K | +90,100 | +$446K |
| Forma Therapeutics | 0.18% | New | 58,700 | $6.88 | $404K | +58,700 | +$404K |
| Marinus Pharmaceuticals | 0.15% | New | 68,900 | $4.83 | $333K | +68,900 | +$333K |
| Optinose | 0.15% | New | 90,970 | $3.66 | $333K | +90,970 | +$333K |
| Avalo Therapeutics | 0.10% | Reduce −69.1% | 450,000 | $0.5000 | $225K | −1,004,400 | −$829K |
| Theseus Pharmaceuticals | 0.08% | New | 32,300 | $5.54 | $179K | +32,300 | +$179K |
| Lumos Pharma | 0.07% | New | 21,520 | $7.71 | $166K | +21,520 | +$166K |
| Biolinerx | 0.01% | Hold | 16,667 | $1.26 | $21K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2022 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| BCYC - Bicycle Therapeutics | 2.38% | Exit | 0 | $43.88 | $8M | −175,000 | −$8M |
| PTGX - Protagonist Therapeutics | 1.85% | Exit | 0 | $23.68 | $6M | −251,500 | −$6M |
| Semler Scientific | 1.08% | Exit | 0 | $49.56 | $3M | −70,000 | −$3M |
| FULC - Fulcrum Therapeutics | 1.00% | Exit | 0 | $23.65 | $3M | −136,000 | −$3M |
| Synlogic | 0.73% | Exit | 0 | $2.40 | $2M | −984,200 | −$2M |
| Aveo Pharmaceuticals | 0.42% | Exit | 0 | $5.59 | $1M | −240,000 | −$1M |
| Nucana | 0.27% | Exit | 0 | $0.9992 | $878K | −878,700 | −$878K |
| Repare Therapeutics | 0.25% | Exit | 0 | $14.24 | $793K | −55,678 | −$793K |
| Sutro Biopharma | 0.23% | Exit | 0 | $8.22 | $740K | −89,980 | −$740K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2